Class C GPCRs in the airway

Curr Opin Pharmacol. 2020 Apr:51:19-28. doi: 10.1016/j.coph.2020.04.002. Epub 2020 May 4.

Abstract

Understanding and targeting of GPCRs remain a critical aspect of airway pharmacology and therapeutics for diseases such as asthma or COPD. Most attention has been on the large Class A GPCRs towards improved bronchodilation and blunting of remodeling. Better known in the central or peripheral nervous system, there is increasing evidence that Class C GPCRs which include metabotropic glutamate and GABA receptors, the calcium sensing receptor, sweet/umami taste receptors and a number of orphan receptors, can contribute to airway structure and function. In this review, we will summarize current state of knowledge regarding the pharmacology of Class C GPCRs, their expression and potential functions in the airways, and the application of pharmacological agents targeting this group in the context of airway diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / trends
  • Humans
  • Lung / drug effects
  • Lung / metabolism*
  • Lung Diseases / drug therapy*
  • Lung Diseases / metabolism*
  • Receptors, Calcium-Sensing / antagonists & inhibitors
  • Receptors, Calcium-Sensing / metabolism
  • Receptors, G-Protein-Coupled / antagonists & inhibitors
  • Receptors, G-Protein-Coupled / metabolism*
  • Receptors, GABA-B / metabolism
  • Respiratory System Agents / administration & dosage*

Substances

  • Receptors, Calcium-Sensing
  • Receptors, G-Protein-Coupled
  • Receptors, GABA-B
  • Respiratory System Agents